サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1739191

m-RNA合成サービスの世界市場

m-RNA Synthesis Services

出版日
ページ情報
英文 227 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.08円
m-RNA合成サービスの世界市場
出版日: 2025年05月23日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 227 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

m-RNA合成サービスの世界市場は2030年までに100億米ドルに達する見込み

2024年に73億米ドルと推定されるm-RNA合成サービスの世界市場は、2024年から2030年にかけてCAGR 5.3%で成長し、2030年には100億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである治療開発アプリケーションは、CAGR 6.6%を記録し、分析期間終了時には44億米ドルに達すると予測されます。ワクチン製造アプリケーション分野の成長率は、分析期間中CAGR 4.2%と推定されます。

米国市場は19億米ドルと推定、中国はCAGR 5.1％で成長すると予測

米国のm-RNA合成サービス市場は、2024年に19億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに16億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは5.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.9％と4.5％と予測されています。欧州では、ドイツがCAGR 4.1%で成長すると予測されています。

世界のm-RNA合成サービス市場- 主要動向と促進要因のまとめ

m-RNA合成サービスが次世代治療薬やワクチンプラットフォームの要になる理由とは？

メッセンジャーRNA（mRNA）合成サービスは、特にmRNAベースのCOVID-19ワクチンに対する世界の注目を受けて、バイオ医薬品エコシステムの基礎となる柱へと急速に進化しています。mRNAはDNAとタンパク質合成の間の一時的な中間体として機能し、治療用途において疾患特異的なタンパク質をコード化するための万能な手段となっています。高純度でGMPグレードの合成mRNAの需要は、ワクチン開発、個別化がん免疫療法、タンパク質代替療法、希少疾患治療などで高まっています。

従来のタンパク質やウイルスベクターをベースとした治療薬とは異なり、mRNAをベースとした治療法は、迅速かつスケーラブルで、無細胞での製造が可能という利点があります。ゲノム統合のリスクを伴わずに標的免疫反応を引き起こすその能力は、感染症予防や腫瘍学に新たな可能性をもたらしています。その結果、医薬品開発者、特にバイオテクノロジー新興企業や学術コンソーシアムは、最適化された転写プロトコル、キャッピング技術、下流の精製専門知識を提供する専門の開発製造受託機関（CDMO）へのmRNA合成のアウトソーシングをますます増やしています。

技術プラットフォームとプロセス革新は、どのようにm-RNA合成サービスの進化を加速しているのか？

mRNA合成の技術的状況は、in vitro転写（IVT）化学、酵素的キャッピング、配列最適化における革新によって急速に進歩しています。合成DNA鋳型はファージRNAポリメラーゼ（例えばT7、SP6）を用いて転写され、鋳型工学の改良により安定性、翻訳効率、免疫回避が向上しています。プソイドウリジンや5-メチルシチジンのような修飾ヌクレオシドは、自然免疫反応を抑え、投与後のmRNAの寿命を改善するために組み込まれています。

キャップアナログ（CleanCapやARCAなど）やポリ（A）テール長の最適化は、現在では日常的に合成ワークフローに組み込まれ、リボソームのリクルートメントと翻訳の忠実度を向上させています。CDMOは、プラスミド直鎖化、IVT反応、DNase治療、クロマトグラフィー精製、無菌充填仕上げを含むエンド・ツー・エンドのサービスを、GMPまたは研究用条件下で提供しています。自動化、シングルユース・バイオリアクター、AIベースの品質分析の統合は、サイクルタイムを短縮し、バッチの一貫性を高め、核酸治療薬に対する規制の期待を確実に遵守しています。

世界的にm-RNA合成サービスの需要を牽引している治療分野と開発者セグメントは？

感染症は、特にModernaとPfizer-BioNTechによるCOVID-19用mRNAワクチンの成功により、依然として最も顕著な治療用途となっています。しかしながら、腫瘍学が次のフロンティアとして急速に台頭してきており、個別化免疫療法のために腫瘍特異的新抗原をコードするためにmRNAが使用されています。調査はまた、心血管系疾患、自己免疫疾患、代謝性疾患、遺伝的欠損症などにも広がっており、そこではmRNAが生体内で機能的タンパク質を発現するようにプログラムされ、一過性ではあるが強力な治療効果をもたらすことができます。

アカデミックラボ、小規模バイオテクノロジー企業、mRNAに特化した新興企業が合成サービスプロバイダーの最も活発な顧客となっているのは、社内のGMP能力が限られており、クリーンルームでのバイオ製造インフラが高コストであるためです。並行して、大手製薬会社は、核酸合成、スケールアップ、製剤化における外部の専門知識を活用し、mRNAパイプラインを拡大するためにCDMOとの提携を増やしています。政府機関や官民パートナーシップも、ワクチン備蓄開発やパンデミック対策を通じて需要を促進しています。

m-RNA合成サービス市場の長期的成長と競合差別化の原動力は？

mRNA合成サービス市場の成長は、mRNAベースの治療薬の適用範囲の拡大、mRNA新興企業へのVC投資の増加、規制当局による核酸ベースの治療法の受け入れの増加によってもたらされます。世界の規制の枠組みは、画期的な治療法や早期承認経路の下で、mRNA候補を迅速に承認するよう適応されつつあり、開発やアウトソーシング活動を後押ししています。個別化医療や新抗原特異的がん治療の台頭は、少量生産でカスタマイズされたmRNA合成サービスへの需要の急増を促しています。

競争の激しい市場で差別化を図るため、サービスプロバイダーはプラットフォームの拡張性、IPで保護されたキャップアナログ、GMPコンプライアンス、脂質ナノ粒子（LNP）製剤サービスとの統合に注力しています。DNAテンプレート製造やRNA安定化技術に垂直統合し、フルサイクルのRNA医薬品開発サポートを提供するところもあります。mRNAが緊急ワクチン用途から主流の治療用途に移行するにつれ、堅牢で信頼性が高く、規制に準拠した合成サービスは、この高成長セグメントにおける技術革新を加速し、商業的成功を確実にするために不可欠となります。

セグメント

用途（治療開発、ワクチン製造、創薬、その他の用途）;事業規模（研究、商業）;エンドユーザー（バイオ製薬会社、契約研究機関、その他のエンドユーザー）

調査対象企業の例（注目の44社）

  • AGC Biologics
  • Aldevron
  • APExBIO
  • Aurigene Pharmaceutical Services
  • Biomay
  • BioNTech SE
  • CELLSCRIPT
  • Creative Biogene
  • CureVac N.V.
  • Eurofins Genomics
  • GENEWIZ（Azenta Life Sciences）
  • GenScript
  • Integrated DNA Technologies
  • Merck KGaA
  • Moderna, Inc.
  • New England Biolabs
  • Samsung Biologics
  • ST Pharm
  • Thermo Fisher Scientific
  • TriLink BioTechnologies

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP34099

Global m-RNA Synthesis Services Market to Reach US$10.0 Billion by 2030

The global market for m-RNA Synthesis Services estimated at US$7.3 Billion in the year 2024, is expected to reach US$10.0 Billion by 2030, growing at a CAGR of 5.3% over the analysis period 2024-2030. Therapeutic Development Application, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$4.4 Billion by the end of the analysis period. Growth in the Vaccine Production Application segment is estimated at 4.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.9 Billion While China is Forecast to Grow at 5.1% CAGR

The m-RNA Synthesis Services market in the U.S. is estimated at US$1.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 5.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.9% and 4.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Global m-RNA Synthesis Services Market - Key Trends & Drivers Summarized

Why Are m-RNA Synthesis Services Becoming a Cornerstone in Next-Generation Therapeutics and Vaccine Platforms?

Messenger RNA (mRNA) synthesis services are rapidly evolving into a foundational pillar of the biopharmaceutical ecosystem, particularly in the wake of global attention on mRNA-based COVID-19 vaccines. mRNA functions as the transient intermediary between DNA and protein synthesis, making it a versatile vehicle for encoding disease-specific proteins in therapeutic applications. The demand for high-purity, GMP-grade synthetic mRNA is growing across vaccine development, personalized cancer immunotherapy, protein replacement therapies, and rare disease treatments.

Unlike traditional protein or viral vector-based therapeutics, mRNA-based modalities offer rapid, scalable, and cell-free manufacturing advantages. Their ability to elicit targeted immune responses without the risk of genome integration has opened up new possibilities in infectious disease prevention and oncology. Consequently, drug developers-especially biotech startups and academic consortia-are increasingly outsourcing mRNA synthesis to specialized contract development and manufacturing organizations (CDMOs) that provide optimized transcription protocols, capping technologies, and downstream purification expertise.

How Are Technology Platforms and Process Innovations Accelerating the Evolution of m-RNA Synthesis Services?

The technological landscape of mRNA synthesis is advancing rapidly through innovations in in vitro transcription (IVT) chemistry, enzymatic capping, and sequence optimization. Synthetic DNA templates are transcribed using phage RNA polymerases (e.g., T7, SP6), with improvements in template engineering enhancing stability, translational efficiency, and immune evasion. Modified nucleosides like pseudouridine and 5-methylcytidine are being incorporated to reduce innate immune responses and improve mRNA longevity post-administration.

Cap analogs (such as CleanCap and ARCA) and poly(A) tail length optimization are now routinely integrated into synthesis workflows, improving ribosome recruitment and translation fidelity. CDMOs are offering end-to-end services-including plasmid linearization, IVT reaction, DNase treatment, chromatographic purification, and sterile fill-finish-under GMP or research-use conditions. The integration of automation, single-use bioreactors, and AI-based quality analytics is reducing cycle times, increasing batch consistency, and ensuring compliance with regulatory expectations for nucleic acid therapeutics.

Which Therapeutic Areas and Developer Segments Are Driving Demand for m-RNA Synthesis Services Globally?

Infectious diseases remain the most prominent therapeutic application, particularly with the success of mRNA vaccines for COVID-19 by Moderna and Pfizer-BioNTech. However, oncology is fast emerging as the next frontier, with mRNA being used to encode tumor-specific neoantigens for individualized immunotherapy. Research is also expanding into cardiovascular diseases, autoimmune conditions, metabolic disorders, and genetic deficiencies-where mRNA can be programmed to express functional proteins in vivo, offering transient but potent therapeutic effects.

Academic labs, small biotech firms, and mRNA-focused startups are the most active clients of synthesis service providers due to limited in-house GMP capabilities and the high cost of cleanroom biomanufacturing infrastructure. In parallel, large pharmaceutical companies are increasingly partnering with CDMOs to expand their mRNA pipelines, leveraging external expertise in nucleic acid synthesis, scale-up, and formulation. Government agencies and public-private partnerships are also fueling demand through vaccine stockpile development and pandemic preparedness initiatives.

What Is Driving Long-Term Growth and Competitive Differentiation in the m-RNA Synthesis Services Market?

The growth in the mRNA synthesis services market is driven by the expanding application scope of mRNA-based therapeutics, growing VC investment in mRNA startups, and increasing acceptance of nucleic acid-based modalities by regulatory agencies. Global regulatory frameworks are being adapted to fast-track mRNA candidates under breakthrough therapy and accelerated approval pathways, encouraging development and outsourcing activity. The rise of personalized medicine and neoantigen-specific cancer therapies is fostering a surge in demand for small-batch, customized mRNA synthesis services.

To differentiate in a competitive market, service providers are focusing on platform scalability, IP-protected cap analogs, GMP compliance, and integration with lipid nanoparticle (LNP) formulation services. Some are vertically integrating into DNA template manufacturing and RNA stabilization technologies to offer full-cycle RNA drug development support. As mRNA transitions from emergency vaccine use to mainstream therapeutic applications, robust, reliable, and regulatory-compliant synthesis services will be essential to accelerating innovation and ensuring commercial success in this high-growth segment.

SCOPE OF STUDY:

The report analyzes the m-RNA Synthesis Services market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Application (Therapeutic Development, Vaccine Production, Drug Discovery, Other Applications); Scale of Operation (Research, Commercial); End-User (Biopharmaceutical Companies, Contract Research Organizations, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 44 Featured) -

  • AGC Biologics
  • Aldevron
  • APExBIO
  • Aurigene Pharmaceutical Services
  • Biomay
  • BioNTech SE
  • CELLSCRIPT
  • Creative Biogene
  • CureVac N.V.
  • Eurofins Genomics
  • GENEWIZ (Azenta Life Sciences)
  • GenScript
  • Integrated DNA Technologies
  • Merck KGaA
  • Moderna, Inc.
  • New England Biolabs
  • Samsung Biologics
  • ST Pharm
  • Thermo Fisher Scientific
  • TriLink BioTechnologies

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • m-RNA Synthesis Services - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Investment in mRNA Therapeutics and Vaccines Drives Demand for Scalable Synthesis Services
    • Expansion of RNA-Based Drug Development Pipelines Throws the Spotlight on Outsourced mRNA Manufacturing
    • Advancements in In Vitro Transcription Technologies Strengthen Process Efficiency and Purity Levels
    • Growth in Personalized Cancer Immunotherapy and Rare Disease Therapies Fuels Use of Custom mRNA Constructs
    • Increased Demand for GMP-Compliant and Clinical-Grade mRNA Production Supports Biopharma Outsourcing
    • Use of Enzymatic Capping, Polyadenylation, and Purification Enhances Bioavailability and Stability
    • Surge in COVID-19 and Pandemic-Preparedness Initiatives Accelerates Infrastructure for Rapid Response mRNA Platforms
    • OEM Collaborations With CDMOs and CROs Drive Standardization of mRNA Workflows
    • Expansion of Synthetic Biology and Modular Plasmid Engineering Supports Multi-Payload Expression Platforms
    • Focus on Scalable In-House Bioreactor and Cell-Free Systems Improves Turnaround for Clinical Trials
    • Use of Lipid Nanoparticle (LNP) and Other Delivery-Compatible Formulations Expands Downstream Integration
    • Regulatory Acceleration and Emergency Use Approvals Strengthen Market Entry for mRNA-Based Products
    • Increased Biotech Startups' Reliance on Contract Synthesis Supports One-Stop mRNA Development Models
    • Focus on High-Fidelity and Sequence-Specific Synthesis Reduces Batch Variability and Contamination Risk
    • Growth in Therapeutic Areas Including HIV, Malaria, Zika, and CMV Expands End-Use Base
    • Government Funding and Pandemic Security Programs Drive Investment in Regional Synthesis Facilities
    • Emergence of Self-Amplifying and Circular RNA Variants Spurs Diversification in Synthesis Capabilities
    • Emphasis on IP Licensing, Codon Optimization, and Proprietary Templates Strengthens Competitive Differentiation
    • Rising Demand for Cell Therapy and Gene Editing Tools Expands Role of mRNA in CRISPR Delivery
    • Digital Twin and Automation Technologies Enhance Precision and Throughput in Custom Synthesis Workflows
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World m-RNA Synthesis Services Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for m-RNA Synthesis Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for m-RNA Synthesis Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Therapeutic Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Therapeutic Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Therapeutic Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Vaccine Production by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Vaccine Production by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Vaccine Production by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Commercial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Commercial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Commercial by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Biopharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • m-RNA Synthesis Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for m-RNA Synthesis Services by Application - Percentage Breakdown of Value Sales for Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Scale of Operation - Research and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for m-RNA Synthesis Services by Scale of Operation - Research and Commercial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for m-RNA Synthesis Services by Scale of Operation - Percentage Breakdown of Value Sales for Research and Commercial for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for m-RNA Synthesis Services by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 41: Canada Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for m-RNA Synthesis Services by Application - Percentage Breakdown of Value Sales for Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Scale of Operation - Research and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for m-RNA Synthesis Services by Scale of Operation - Research and Commercial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for m-RNA Synthesis Services by Scale of Operation - Percentage Breakdown of Value Sales for Research and Commercial for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for m-RNA Synthesis Services by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
  • JAPAN
    • m-RNA Synthesis Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 50: Japan Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for m-RNA Synthesis Services by Application - Percentage Breakdown of Value Sales for Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 53: Japan Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Scale of Operation - Research and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for m-RNA Synthesis Services by Scale of Operation - Research and Commercial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for m-RNA Synthesis Services by Scale of Operation - Percentage Breakdown of Value Sales for Research and Commercial for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for m-RNA Synthesis Services by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
  • CHINA
    • m-RNA Synthesis Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for m-RNA Synthesis Services by Application - Percentage Breakdown of Value Sales for Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Scale of Operation - Research and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for m-RNA Synthesis Services by Scale of Operation - Research and Commercial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for m-RNA Synthesis Services by Scale of Operation - Percentage Breakdown of Value Sales for Research and Commercial for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for m-RNA Synthesis Services by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
  • EUROPE
    • m-RNA Synthesis Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 68: Europe Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for m-RNA Synthesis Services by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for m-RNA Synthesis Services by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for m-RNA Synthesis Services by Application - Percentage Breakdown of Value Sales for Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Scale of Operation - Research and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for m-RNA Synthesis Services by Scale of Operation - Research and Commercial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for m-RNA Synthesis Services by Scale of Operation - Percentage Breakdown of Value Sales for Research and Commercial for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for m-RNA Synthesis Services by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
  • FRANCE
    • m-RNA Synthesis Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 80: France Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for m-RNA Synthesis Services by Application - Percentage Breakdown of Value Sales for Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 83: France Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Scale of Operation - Research and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for m-RNA Synthesis Services by Scale of Operation - Research and Commercial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for m-RNA Synthesis Services by Scale of Operation - Percentage Breakdown of Value Sales for Research and Commercial for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for m-RNA Synthesis Services by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
  • GERMANY
    • m-RNA Synthesis Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 89: Germany Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for m-RNA Synthesis Services by Application - Percentage Breakdown of Value Sales for Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 92: Germany Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Scale of Operation - Research and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for m-RNA Synthesis Services by Scale of Operation - Research and Commercial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for m-RNA Synthesis Services by Scale of Operation - Percentage Breakdown of Value Sales for Research and Commercial for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for m-RNA Synthesis Services by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 98: Italy Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for m-RNA Synthesis Services by Application - Percentage Breakdown of Value Sales for Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 101: Italy Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Scale of Operation - Research and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for m-RNA Synthesis Services by Scale of Operation - Research and Commercial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for m-RNA Synthesis Services by Scale of Operation - Percentage Breakdown of Value Sales for Research and Commercial for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for m-RNA Synthesis Services by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • m-RNA Synthesis Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 107: UK Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for m-RNA Synthesis Services by Application - Percentage Breakdown of Value Sales for Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 110: UK Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Scale of Operation - Research and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for m-RNA Synthesis Services by Scale of Operation - Research and Commercial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for m-RNA Synthesis Services by Scale of Operation - Percentage Breakdown of Value Sales for Research and Commercial for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for m-RNA Synthesis Services by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Rest of Europe Historic Review for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Rest of Europe 15-Year Perspective for m-RNA Synthesis Services by Application - Percentage Breakdown of Value Sales for Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Scale of Operation - Research and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Rest of Europe Historic Review for m-RNA Synthesis Services by Scale of Operation - Research and Commercial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Rest of Europe 15-Year Perspective for m-RNA Synthesis Services by Scale of Operation - Percentage Breakdown of Value Sales for Research and Commercial for the Years 2015, 2025 & 2030
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Europe Historic Review for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Europe 15-Year Perspective for m-RNA Synthesis Services by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • m-RNA Synthesis Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 125: Asia-Pacific Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Asia-Pacific Historic Review for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Asia-Pacific 15-Year Perspective for m-RNA Synthesis Services by Application - Percentage Breakdown of Value Sales for Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Scale of Operation - Research and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for m-RNA Synthesis Services by Scale of Operation - Research and Commercial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Asia-Pacific 15-Year Perspective for m-RNA Synthesis Services by Scale of Operation - Percentage Breakdown of Value Sales for Research and Commercial for the Years 2015, 2025 & 2030
    • TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Asia-Pacific Historic Review for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Asia-Pacific 15-Year Perspective for m-RNA Synthesis Services by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 134: Rest of World Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of World Historic Review for m-RNA Synthesis Services by Application - Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of World 15-Year Perspective for m-RNA Synthesis Services by Application - Percentage Breakdown of Value Sales for Therapeutic Development, Vaccine Production, Drug Discovery and Other Applications for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of World Recent Past, Current & Future Analysis for m-RNA Synthesis Services by Scale of Operation - Research and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of World Historic Review for m-RNA Synthesis Services by Scale of Operation - Research and Commercial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of World 15-Year Perspective for m-RNA Synthesis Services by Scale of Operation - Percentage Breakdown of Value Sales for Research and Commercial for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of World Recent Past, Current & Future Analysis for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of World Historic Review for m-RNA Synthesis Services by End-user - Biopharmaceutical Companies, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of World 15-Year Perspective for m-RNA Synthesis Services by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030

IV. COMPETITION